Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 0.86 |
| ▸ | NSD2 | O96028 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.61 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.61 |
| ▸ | TYR | P14679 | 2/20 | 0.55 |
| ▸ | SELL | P14151 | 1/20 | 0.53 |
| ▸ | SELP | P16109 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037701 | 1.00 | SERPINE1 (0.86) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL2788238 | 0.92 | SERPINE1 (1.00) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL28099223 | 0.89 | SERPINE1 (0.79) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL30257849 | 0.89 | SERPINE1 (0.93) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| Hydrochloric Acid SCHEMBL30257174 | 0.87 | SERPINE1 (0.77) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL29008677 | 0.86 | SERPINE1 (0.74) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL30307878 | 0.86 | SERPINE1 (0.74) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL10783800 | 0.85 | SERPINE1 (0.62) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL4736135 | 0.84 | SERPINE1 (0.77) | SERPINE1NSD2POLBPOLA1ANTXR2 | |
| SCHEMBL4737505 | 0.84 | SERPINE1 (0.83) | SERPINE1NSD2POLBPOLA1ANTXR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605496-A | Polypeptide and application thereof, antibacterial drug and preparation method thereof | 华中科技大学 | 2022-06-10 | — | — | CN | claimed |
| CN-104673772-A | Composite enzymolysis reagent for keratin enzymolysis and application method thereof | HUZHOU ZHENBEI CASHMERE PRODUCTS CO LTD | 2015-06-03 | — | — | CN | claimed |
| CN-101415341-B | Formulation containing a polyphenol-containing composition and isomaltulose | ZJUDTSUKER AKTSIENGEZELL SHAFT MANNKHAJM OKZENFURT | 2012-09-05 | — | — | CN | claimed |
| US-20110166219-A1 | USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRECANCEROUS LESION OF THE SKIN | MEDIGENE AG (DE) | 2011-07-07 | — | — | US | claimed |
| EP-2292226-A2 | The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin | MediGene AG (DE) | 2011-03-09 | — | — | EP | claimed |
| CN-101415341-A | Formulation containing a polyphenol-containing composition and isomaltulose | SUEDZUCKER AG (DE) | 2009-04-22 | — | — | CN | claimed |
| US-20070059387-A1 | Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin | MEDIGENE AG (DE) | 2007-03-15 | — | — | US | claimed |
| EP-1684780-A1 | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN | Medigene AG (DE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005037300-A1 | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN | MEDIGENE AG (DE) | 2005-04-28 | — | — | WO | claimed |
| US-20050079235-A1 | Use of a polyphenol for the treatment of actinic keratosis | MEDIGENE AG (DE) | 2005-04-14 | — | — | US | claimed |
| CN-114605496-B | Polypeptide and application thereof, antibacterial drug and preparation method thereof | 华中科技大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-114605496-A | Polypeptide and application thereof, antibacterial drug and preparation method thereof | 华中科技大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-108474047-B | Detection solution for detecting whether leather is treated with 6-valent chromium reducing compound | 西铁城时计株式会社 | 2021-03-23 | — | — | CN | disclosed |
| CN-108463563-B | Method for producing reptile leather or leather product using 6-valent chromium treatment agent, and reptile leather or leather product using 6-valent chromium treatment agent | 西铁城时计株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-108473846-B | 6-valent chromium treating agent and leather or leather product using same | 西铁城时计株式会社 | 2020-10-23 | — | — | CN | disclosed |
| CN-101415341-A | Formulation containing a polyphenol-containing composition and isomaltulose | SUEDZUCKER AG (DE) | 2009-04-22 | — | — | CN | disclosed |
| US-20070059387-A1 | Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin | MEDIGENE AG (DE) | 2007-03-15 | — | — | US | disclosed |
| EP-1684780-A1 | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN | Medigene AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005037300-A1 | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRE-CANCEROUS LESION OF THE SKIN | MEDIGENE AG (DE) | 2005-04-28 | — | — | WO | disclosed |
| US-20050079235-A1 | Use of a polyphenol for the treatment of actinic keratosis | MEDIGENE AG (DE) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166219-A1 | USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROUS OR PRECANCEROUS LESION OF THE SKIN | MKI67, NQO1, VHL | SERPINE1 565/4885NSD2 2480/4885POLB 937/4885 |
| US-20050079235-A1 | Use of a polyphenol for the treatment of actinic keratosis | KRT18, MKI67, ACTB | SERPINE1 696/4885NSD2 4403/4885POLB 891/4885 |
| US-20070059387-A1 | Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin | MKI67, NQO1, VHL | SERPINE1 581/4885NSD2 2911/4885POLB 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.